Therapeutic effect of lecithinized superoxide dismutase Against colitis

Journal of Pharmacology and Experimental Therapeutics

Volumn 328, Issue 1, 2009, Pages 152-164

  Ishihara, Tomoaki ^a,b   Tanaka, Ken Ichiro ^a   Tasaka, Yuichi ^a   Namba, Takushi ^a   Suzuki, Jun ^a   Ishihara, Tsutomu ^a   Okamoto, Susumu ^c   Hibi, Toshifumi ^c   Takenaga, Mitsuko ^d   Igarashi, Rie ^d   Sato, Keizo ^a   Mizushima, Yutaka ^a,b   Mizushima, Tohru ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; DEXTRAN SULFATE; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELOPEROXIDASE; PHOSPHATIDYLCHOLINE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; COMPLEMENTARY DNA; INTERLEUKIN 1; INTERLEUKIN 23; INTERLEUKIN 6; LECITHINIZED SUPEROXIDE DISMUTASE; PEROXIDASE; PRIMER DNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; DRUG TISSUE LEVEL; ELECTRON SPIN RESONANCE; ENZYME ACTIVITY; GENE EXPRESSION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; ULCERATIVE COLITIS; ANIMAL; COLON; ENZYMOLOGY; GENETICS; HUMAN; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CATALASE; COLITIS, ULCERATIVE; COLON; DNA PRIMERS; DNA, COMPLEMENTARY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1; INTERLEUKIN-23; INTERLEUKIN-6; INTESTINAL MUCOSA; MICE; NEUTROPHILS; PEROXIDASE; PHOSPHATIDYLCHOLINES; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUPEROXIDE DISMUTASE;

EID: 59149097248     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.144451     Document Type: Article

References (40)

1. Baumgart DC and Sandborn WJ (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369:1641-1657.
2. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, and Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275-2285.
3. Broeyer FJ, van Aken BE, Suzuki J, Kemme MJ, Schoemaker HC, Cohen AF, Mizushima Y, and Burggraaf J (2008) The pharmacokinetics and effects of a long-acting preparation of superoxide dismutase (PC-SOD) in man. Br J Clin Pharmacol 65:22-29.
4. Chikawa T, Ikata T, Katoh S, Hamada Y, Kogure K, and Fukuzawa K (2001) Preventive effects of lecithinized superoxide dismutase and methylprednisolone on spinal cord injury in rats: transcriptional regulation of inflammatory and neurotrophic genes. J Neurotrauma 18:93-103.
5. Cuzzocrea S (2003) Emerging biotherapies for inflammatory bowel disease. Expert Opin Emerg Drugs 8:339-347.
6. den Hartog GJ, Haenen GR, Boven E, van der Vijgh WJ, and Bast A (2004) Lecithinized copper,zinc-superoxide dismutase as a protector against doxorubicin-induced cardiotoxicity in mice. Toxicol Appl Pharmacol 194:180-188.
7. Greenwald RA (1990) Superoxide dismutase and catalase as therapeutic agents for human diseases: a critical review. Free Radic Biol Med 8:201-209.
8. Herfarth H, Brand K, Rath HC, Rogler G, Scholmerich J, and Falk W (2000) Nuclear factor-kappa B activity and intestinal inflammation in dextran sulphate sodium (DSS)-induced colitis in mice is suppressed by gliotoxin. Clin Exp Immunol 120:59-65.
9. Hori Y, Hoshino J, Yamazaki C, Sekiguchi T, Miyauchi S, Mizuno S, and Horie K (1997) Effect of lecithinized-superoxide dismutase on the rat colitis model induced by dextran sulfate sodium. Jpn J Pharmacol 74:99-103.
10. Igarashi R, Hoshino J, Ochiai A, Morizawa Y, and Mizushima Y (1994) Lecithinized superoxide dismutase enhances its pharmacologic potency by increasing its cell membrane affinity. J Pharmacol Exp Ther 271:1672-1677.
11. Igarashi R, Hoshino J, Takenaga M, Kawai S, Morizawa Y, Yasuda A, Otani M, and Mizushima Y (1992) Lecithinization of superoxide dismutase potentiates its protective effect against Forssman antiserum-induced elevation in guinea pig airway resistance. J Pharmacol Exp Ther 262:1214-1219.
12. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
13. Karakawa T, Sato K, Muramoto Y, Mitani Y, Kitamado M, Iwanaga T, Nabeshima T, Maruyama K, Nakagawa K, Ishida K, et al. (2008) Applicability of new spin trap agent, 2-diphenylphosphinoyl-2-methyl-3,4-dihydro-2H-pyrrole N-oxide, in biological system. Biochem Biophys Res Commun 370:93-97.
14. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, and Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098-1104.
15. Keshavarzian A, Morgan G, Sedghi S, Gordon JH, and Doria M (1990) Role of reactive oxygen metabolites in experimental colitis. Gut 31:786-790.
16. Kruidenier L, Kuiper I, van Duijn W, Marklund SL, van Hogezand RA, Lamers CB, and Verspaget HW (2003a) Differential mucosal expression of three superoxide dismutase isoforms in inflammatory bowel disease. J Pathol 201:7-16.
17. Kruidenier L, Kuiper I, Van Duijn W, Mieremet-Ooms MA, van Hogezand RA, Lamers CB, and Verspaget HW (2003b) Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J Pathol 201:17-27.
18. Kruidenier L, van Meeteren ME, Kuiper I, Jaarsma D, Lamers CB, Zijlstra FJ, and Verspaget HW (2003c) Attenuated mild colonic inflammation and improved survival from severe DSS-colitis of transgenic Cu/Zn-SOD mice. Free Radic Biol Med 34:753-765.
19. Kruidenier L and Verspaget HW (2002) Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease-radicals or ridiculous? Aliment Pharmacol Ther 16:1997-2015.
20. Mahgoub AA, El-Medany AA, Hager HH, Mustafa AA, and El-Sabah DM (2003) Evaluating the prophylactic potential of zafirlukast against the toxic effects of acetic acid on the rat colon. Toxicol Lett 145:79-87.
21. Mao GD, Thomas PD, Lopaschuk GD, and Poznansky MJ (1993) Superoxide dismutase (SOD)-catalase conjugates: role of hydrogen peroxide and the Fenton reaction in SOD toxicity. J Biol Chem 268:416-420.
22. Marikovsky M, Ziv V, Nevo N, Harris-Cerruti C, and Mahler O (2003) Cu/Zn superoxide dismutase plays important role in immune response. J Immunol 170:2993-3001.
23. Mima S, Tsutsumi S, Ushijima H, Takeda M, Fukuda I, Yokomizo K, Suzuki K, Sano K, Nakanishi T, Tomisato W, et al. (2005) Induction of claudin-4 by nonsteroidal anti-inflammatory drugs and its contribution to their chemopreventive effect. Cancer Res 65:1868-1876.
24. Muranaka H, Suga M, Sato K, Nakagawa K, Akaike T, Okamoto T, Maeda H, and Ando M (1997) Superoxide scavenging activity of erythromycin-iron complex. Biochem Biophys Res Commun 232:183-187.
25. Nakajima H, Hangaishi M, Ishizaka N, Taguchi J, Igarashi R, Mizushima Y, Nagai R, and Ohno M (2001) Lecithinized copper, zinc-superoxide dismutase ameliorates ischemia-induced myocardial damage. Life Sci 69:935-944.
26. Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347:417-429.
27. Salimuddin, Nagasaki A, Gotoh T, Isobe H, and Mori M (1999) Regulation of the genes for arginase isoforms and related enzymes in mouse macrophages by lipo-polysaccharide. Am J Physiol 277:E110-E117.
28. 2 plus Cu,Zn-superoxide dismutase reflects the activity of free copper released from the oxidatively damaged enzyme. J Biol Chem 267:25371-25377.
29. Sato K, Kadiiska MB, Ghio AJ, Corbett J, Fann YC, Holland SM, Thurman RG, and Mason RP (2002) In vivo lipid-derived free radical formation by NADPH oxidase in acute lung injury induced by lipopolysaccharide: a model for ARDS. FASEB J 16:1713-1720.
30. Schmidt KN, Amstad P, Cerutti P, and Baeuerle PA (1995) The roles of hydrogen peroxide and superoxide as messengers in the activation of transcription factor NF-kappa B. Chem Biol 2:13-22.
31. Schreiber S, Nikolaus S, and Hampe J (1998) Activation of nuclear factor kappa B inflammatory bowel disease. Gut 42:477-484.
32. Seguí J, Gironella M, Sans M, Granell S, Gil F, Gimeno M, Coronel P, Piqué JM, and Panés J (2004) Superoxide dismutase ameliorates TNBS-induced colitis by reducing oxidative stress, adhesion molecule expression, and leukocyte recruitment into the inflamed intestine. J Leukoc Biol 76:537-544.
33. Simmonds NJ, Allen RE, Stevens TR, Van Someren RN, Blake DR, and Rampton DS (1992) Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology 103:186-196.
34. Suzuki J, Broeyer F, Cohen A, Takebe M, Burggraaf J, and Mizushima Y (2008a) Pharmacokinetics of PC-SOD, a lecithinized recombinant superoxide dismutase, after single- and multiple-dose administration to healthy Japanese and Caucasian volunteers. J Clin Pharmacol 48:184-192.
35. Suzuki Y, Matsumoto T, Okamoto S, and Hibi T (2008b) A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis. Colorectal Dis 10:931-934.
36. Tamagawa K, Taooka Y, Maeda A, Hiyama K, Ishioka S, and Yamakido M (2000) Inhibitory effects of a lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 161:1279-1284.
37. Tanaka K, Namba T, Arai Y, Fujimoto M, Adachi H, Sobue G, Takeuchi K, Nakai A, and Mizushima T (2007) Genetic evidence for a protective role for heat shock factor 1 and heat shock protein 70 against Colitis. J Biol Chem 282:23240-23252.
38. Tsao C, Greene P, Odlind B, and Brater DC (1991) Pharmacokinetics of recombinant human superoxide dismutase in healthy volunteers. Clin Pharmacol Ther 50:713-720.
39. Tsubokawa T, Jadhav V, Solaroglu I, Shiokawa Y, Konishi Y, and Zhang JH (2007) Lecithinized superoxide dismutase improves outcomes and attenuates focal cerebral ischemic injury via antiapoptotic mechanisms in rats. Stroke 38:1057-1062.
40. Yasui K and Baba A (2006) Therapeutic potential of superoxide dismutase (SOD) for resolution of inflammation. Inflamm Res 55:359-363.